PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

S. Loibl, Ian J. Majewski, Valentina Guarneri, Valentina Nekljudova, Eileen Holmes, Emilio Bria, Carsten Denkert, Christian Schem, Christos Sotiriou, Sherene Loi,

Annals of Oncology · 2016 · 228 citations · 26 references

DOIFull text

Open access

Concepts

References

26